Cobicistat: A Novel Pharmacoenhancer for Co-Formulation with HIV Protease and Integrase Inhibitors

Infectious Diseases and Therapy

Volumn 2, Issue 2, 2013, Pages 111-122

  Nathan, Bavithra ^a   Bayley, Jake ^a   Waters, Laura ^b   Post, Frank A ^c  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Boosting; Cobicistat; eGFR; HIV; Infection; Pharmacology; Renal; Stribild; Virology

Indexed keywords

ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; CLARITHROMYCIN; COBICISTAT; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; CYTOCHROME P450 3A4; DARUNAVIR; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ELVITEGRAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FLUTICASONE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTEGRASE INHIBITOR; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1; RITONAVIR; SIMVASTATIN; TENOFOVIR ALAFENAMIDE; TENOFOVIR DISOPROXIL;

CLINICAL TRIAL (TOPIC); CREATININE CLEARANCE; DIARRHEA; DIZZINESS; DRUG POTENTIATION; FANCONI RENOTUBULAR SYNDROME; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAUNDICE; KIDNEY FAILURE; NAUSEA; NEPHROTOXICITY; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84977139614     PISSN: 21938229     EISSN: 21936382     Source Type: Journal    
DOI: 10.1007/s40121-013-0013-7     Document Type: Review

References (37)

1. Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med. 2012;13(Suppl 2): 1-85.
2. Cohen CJ, Molina JM, Cahn P, Clotet B, Fourie J, Grinsztejn B, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. J Acquir Immune Defic Syndr. 2012;60(1): 33-42.
3. Nelson M, Girard PM, Demasi R, Chen L, Smets E, Sekar V, et al. Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data. J Antimicrob Chemother. 2010;65(7): 1505-9.
4. Elzi L, Marzolini C, Furrer H, Ledergerber B, Cavassini M, Hirschel B, et al. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med. 2010;170(1): 57-65.
5. Cooper V, Moyle GJ, Fisher M, Reilly G, Ewan J, Liu HC, et al. Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz. AIDS Care. 2011;23(6): 705-13.
6. Duran S, Spire B, Raffi F, Walter V, Bouhour D, Journot V, et al. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials. 2001;2(1): 38-45.
7. Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination. Lancet. 2009;374(9692): 796-806.
8. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based. JAMA. 2011;305(13): 1327-35.
9. Gianotti N, Tiberi S, Menzo S, Danise A, Boeri E, Galli L, et al. HIV-1 replication capacity and genotype changes in patients undergoing treatment. J Med Virol. 2008;80(2): 201-8.
10. Mathias AA, Germa P, Lee M, et al. GS-9350: a pharmacoenhancer without anti-HIV activity. In: 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada; February 8-11, 2009.
11. Zolopa A, Ortiz R, Sax P, et al. Comparative study of tenofovir alafenamide vs tenofovir disoproxil fumarate, each with elvitegravir, cobicistat, and emtricitabine, for HIV treatment. In: 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, USA; March 3-6, 2013.
12. Hull MW, Montaner JS. Ritonavir-boosted protease inhibitors in HIV therapy. Ann Med. 2011;43(5): 375-88.
13. Squires KE, Young B, DeJesus E, Bellos N, Murphy D, Ward D, et al. ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine. HIV Clin Trials. 2012;13(5): 233-44.
14. Collot-Teixeira S, De Lorenzo F, Waters L, Fletcher C, Back D, Mandalia S, et al. Impact of different low-dose ritonavir regimens on lipids, CD36, and adipophilin expression. Clin Pharmacol Ther. 2009;85(4): 375-8.
15. Ramanathan S, Warren D, Wei L, Kearney BP. Pharmacokinetic boosting of atazanavir with the pharmacoenhancer GS-9350 versus ritonavir. In: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, USA; September 12-15, 2009.
16. German P, Mathias A, Wei L, Murray B, Warren D, Kearney B. The effect of cobicistat on cytochrome P450 2D6, 2B6 and P-glycoprotein using phenotypic probes. In: 12th International Workshop on Clinical Pharmacology of HIV Therapy. Miami, USA; April 13-15, 2011.
17. Lepist E-I, Murray B, Tong L, et al. Effect of cobicistat and ritonavir on proximal renal tubular cell uptake and efflux transporters. In: 61st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, USA; September 17-20, 2011.
18. Rockstroh JK, DeJesus E, Henry K, et al. Elvitegravir/cobicistat/emtricitabine/tenofovir DF (STB) has durable efficacy and differentiated safety compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF in treatment-naïve HIV-1 infected patients: week 96 results. In: 11th International Congress on Drug Therapy in HIV Infection. Glasgow, UK; November 11-16, 2012.
19. Zolopa A, Gallant J, Cohen C, et al. Elvitegravir/cobicistat/emtricitabine/tenofovir DF (STB) has durable efficacy and differentiated safety compared to efavirenz/emtricitabine/tenofovir DF (ATR) in treatment-naïve HIV-1 infected patients: week 96 results. In: 11th International Congress on Drug Therapy in HIV Infection. Glasgow, UK; November 11-15, 2012.
20. Elion R, Cohen C, Gathe J, Shalit P, Hawkins T, Liu HC, et al. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection. AIDS. 2011;25(15): 1881-6.
21. Mathias A, Liu H, Warren D, Sekar V, Kearney BP. Relative bioavailability and pharmacokinetics of darunavir when boosted with the pharmacoenhancer GS-9350 versus ritonavir. In: 11th International Workshop on Clinical Pharmacology of HIV Therapy. Sorrento, Italy; April 7-9, 2010.
22. Ramanathan S, Wang H, Szwarcberg J, Kearney BP. Safety/tolerability, pharmacokinetics, and boosting of twice-daily cobicistat administered alone or in combination with darunavir or tipranavir. In: 13th International Workshop on Clinical Pharmacology of HIV Therapy. Barcelona, Spain; April 16-18, 2012.
23. German P, Warren D, Wei L, Zhong L, Hui J, Kearney BP. Effect of food on pharmacokinetics of elvitegravir, emtricitabine, tenofovir DF and the pharmacoenhancer GS-9350 as a fixed-dose combination tablet. In: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, USA; September 12-15, 2009.
24. Mathias A, Koziara J, Wei X, Warren D, Kearney BP. Effect of acid reducing agents on the relative bioavailability and pharmacokinetics of cobicistat-boosted elvitegravir. In: International Workshop on Clinical Pharmacology of HIV Therapy. Miami, USA; April 13-15, 2010.
25. German P, Wei X, Mizuno V, Cheng A, Kearney BP, Mathias A. Pharmacokinetics of elvitegravir and cobicistat in subjects with severe renal impairment. In: 13th International Workshop on Clinical Pharmacology of HIV Therapy. Barcelona, Spain; April 16-18, 2012.
26. Ramanathan S, Rhee M, Shen G, Custodio J, Kearney BP. Pharmacokinetics and safety of boosted-elvitegravir in subjects with hepatic impairment. In: 13th International Workshop on Clinical Pharmacology of HIV Therapy. Barcelona, Spain; April 16-18, 2012.
27. Ramanathan S, Wei X, Custodio J, Wang H, Dave A, Cheng A, Kearney BP. Pharmacokinetics of EVG/COBI/FTC/TDF single tablet regimen following treatment with EFV/FTC/TDF (Atripla®) in healthy subjects. In: 13th International Workshop on Clinical Pharmacology of HIV Therapy. Barcelona, Spain; April 16-18, 2012.
28. HIV Drug Interactions webpage. http://www. HIV-druginteractions. org. Last accessed 20 Aug 2013.
29. Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012;379(9835): 2439-48.
30. DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012;379(9835): 2429-38.
31. Zolopa A, Sax PE, Dejesus E, Mills A, Cohen C, Wohl D, et al. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for Initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013;63(1): 96-100.
32. Rockstroh JK, Dejesus E, Henry K, Molina JM, Gathe J, Ramanathan S, et al. A randomized, double-blind comparison of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013;62(5): 483-6.
33. Gallant JE, Koenig E, Andrade-Villanueva J, Chetchotisakd P, Dejesus E, Antunes F, et al. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results. J Infect Dis. 2013;208(1): 32-9.
34. Mills A, Crofoot G, Ortiz R, Rashbaum B, Towner W, Ward D, et al. Safety and tolerability of switching from twice daily raltegravir plus truvada to stribild in virologically suppressed, HIV-1 infected subjects. Frontiers in Drug Development for Antiretroviral Therapies. San Diego, CA, USA; December 4-7, 2012.
35. German P, Liu HC, Szwarcberg J, Hepner M, Andrews J, Kearney BP, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr. 2012;61(1): 32-40.
36. Post F, Winston J, Andrade-Villanueva J, Fisher M, Liu Y, Zhong L, et al. Elvitegravir/cobicistat/tenofovir DF/emtricitabine (STB) and cobicistat (COBI) in HIV infected patients with mild to moderate renal impairment. In: 7th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. Kuala Lumpur, Malaysia; 30 June-03 July 2013.
37. Post FA, Holt SG. Recent developments in HIV and the kidney. Curr Opin Infect Dis. 2009;22(1): 43-8.